Navigation Links
SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
Date:8/7/2008

.

We had approximately $8.0 million in cash and cash equivalents, and $564,000 in restricted cash as of June 30, 2008. In addition, we expect to receive an additional $3.1 million in October 2008, related to our Lease Termination Agreement. We believe that our cash, cash equivalents and short- term investments will be sufficient to fund our operations at planned levels through the end of 2009.

Conference Call

As previously announced, SCOLR Pharma will host a conference call on August 7, 2008, at 11:30 a.m. (Eastern Daylight Time). Shareholders and other interested parties may participate in the conference call by dialing +1 888 680 0878 (domestic) or +1 617 213 4855 (international) and entering access code 26733631, a few minutes before 11:30 a.m. ET on August 7, 2008. The call will also be broadcast live on the Internet at http://www.streetevents.com, http://www.fulldisclosure.com or http://www.scolr.com.

A replay of the conference call will be accessible two hours after its completion through August 21, 2008, by dialing +1 888 286 8010 (domestic) or +1 617 801 6888 (international) and entering access code 55141034. The call will also be archived for 90 days at http://www.streetevents.com, http://www.fulldisclosure.com or http://www.scolr.com.

About SCOLR Pharma:

Based in Bellevue, Washington, SCOLR Pharma, Inc. is a specialty pharmaceutical company. SCOLR Pharma's corporate objective is to combine its formulation expertise and its patented CDT platform to develop novel pharmaceutical, over-the-counter (OTC), and nutritional products. Our CDT drug delivery platform is based on multiple issued and pending
'/>"/>

SOURCE SCOLR Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. SCOLR Pharma, Inc. Schedules Second Quarter 2008 Financial Results Conference Call for August 7, 2008 at 11:30 A.M. Eastern
2. GeoPharma, Inc. Receives FDA Approval to Manufacture and Distribute Carprofen
3. Novo Nordisk Inc. Announces Exclusive Agreement With Sciele Pharma, Inc. to Market Prandin(R)
4. China Biopharma, Inc. Announces New Plan of Operation
5. Meritage Pharma, Inc. Announces Company Formation and $22.5M Series A Financing
6. CB1400, Patented by Canopus BioPharma, Prevents Tumor Growth and Enhances the Anti-Tumor Effects of Cisplatin and Cetuximab (Erbitux).
7. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
8. QMed, Inc. Reports July Medicare SNP Enrollments
9. Phlo Affiliate Reports Expanded Coverage to Oregon Border
10. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
11. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... , July 28, 2015 CSL Behring ... Administration has accepted for review the company,s Biologics License ... single-chain (rVIII-SingleChain) for the treatment of hemophilia A. In ... Hemophilia A is a ... VIII; nearly all affected patients are male. People with ...
(Date:7/28/2015)... ZIONA, Israel , July 28, ... OTC:CQPTY), a regenerative medicine company utilizing its proprietary ... announced that Shomrat Shurtz has been appointed Senior ...      (Photo: http://photos.prnewswire.com/prnh/20150728/246955 ) ... years of experience in marketing, regulatory and business ...
(Date:7/27/2015)... and FRANKLIN, Tenn. , July ... premier provider of health care services and one ... U.S., today announced that its parent company and ... definitive agreement with Medical Properties Trust, Inc. ("MPT") ... Capella for $900 million in cash.  The transaction is expected ...
(Date:7/27/2015)... ... July 27, 2015 , ... Production of high tenacity filament yarn of ... in the EU. For instance, it surpassed the EUR 106 million mark (in value ... 2010. Germany is a major producer, while Italy is a key consumer. , ...
Breaking Biology Technology:U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3CollPlant Names Shomrat Shurtz Senior Director of Business Development 2Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 2Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 3Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 4Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 5High Tenacity Filament Yarn of Viscose Rayon Consumption to Grow Swiftly in the EU, Forecasts BAC Reports in New Study Available at MarketPublishers.com 2
... an information technology and Web products and services provider ... announced today that St. Luke,s Hospital & Health Network ... remote 24/7/365 IT infrastructure monitoring from CareTech,s Healthcare Infrastructure ... and monitoring of data, systems and applications located in ...
... innovative medical imaging informatics company, today announced the commercial ... Edition. Following the April release of their first commercial ... commercial version of their widely accepted DICOM ImageServer software, ... With the release of the PACS, Team Edition, ...
... windows which, thanks to a nanocoating, adjust their level ... to save energy; novel diagnostic methods and tailor-made nano-medicines ... one hand, can be used to make very efficient ... pheromones, protect vineyards from insect attack; new nanostructured materials ...
Cached Biology Technology:St. Luke's Hospital & Health Network Selects CareTech Solutions to Provide Proactive Monitoring of Hospital IT Infrastructure 2St. Luke's Hospital & Health Network Selects CareTech Solutions to Provide Proactive Monitoring of Hospital IT Infrastructure 3ClearCanvas Releases First Commercial Version of Widely Used PACS; Integrated RIS/PACS to Follow 2A world without nano? Soon hard to imagine 2A world without nano? Soon hard to imagine 3
(Date:6/30/2015)... Pa. , June 30, 2015 ... the company as CEO to help further develop Genisphere,s ... wealth of partnering experience, having spent much of the ... including Therakine, Amgen, Baxter Bioscience, and Johnson & Johnson. ... focus on Technology and Biotech Corporate Finance. He graduated ...
(Date:6/25/2015)... , June 25, 2015 ... Sensors Market by Type (Swipe & Area), Technology, Material ... Government, Healthcare, Commercial Security & Others) & Geography ... by marketsandmarkets, the said market is expected to ... of 17.1%. Browse 76 market ...
(Date:6/24/2015)... The biologics safety testing market is growing ... market include growth of the pharmaceutical and biological industries ... the years, the number of drug approvals in North ... FDA approved 225 drug applications and Health Canada approved ... accounted for 3,822 of the pharmaceutical and ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4
... 2008 American Society for Microbiology (ASM) Siemens ... presented to Adrian M. Zelazny, Staff Scientist, ... Institutes of Health (NIH). This award recognizes ... antimicrobial therapy. Dr. Zelazny is honored ...
... of supercomputers have hardware set up not just for ... seemingly random data. And now, a multi-institutional group of ... for these supercomputers. Applications include anywhere complex webs of ... grid stability to complex biological networks. The ...
... from infecting other cells and triggering their destruction by ... HIV-infected individuals but eventually peters out. To find out ... Infectious Diseases examined the cells that make the antibodies, ... that HIV gradually depletes the numbers of healthy, functional ...
Cached Biology News:Multithreaded supercomputer seeks software for data-intensive computing 2Multithreaded supercomputer seeks software for data-intensive computing 3
... cell-based assays utilize the membrane-permeant ester ... negatively charged fluorescent beta-lactamase substrates, CCF2 ... enter the cell, where cleavage by ... into their negatively charged forms, thereby ...
...
Homogenizing Solution, 18ml Proteinase K - [50ug/l] 75 l...
...
Biology Products: